First-line Treatment of Advanced/unresectable DDLPS
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFudan University
About this trial
Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma
Eligibility criteria
Qualifiers
Age 18-75 years, male or female;
Histologically confirmed dedifferentiated liposarcoma;
metastatic stage not having received systemic therapy;
no brain metastases;
Disqualifiers
patients with recurrence within six months of postoperative adjuvant therapy;
previous adjuvant or neoadjuvant phase with cumulative dose of doxorubicin, liposomal doxorubicin, or other anthracyclines ≥ 240 mg/m2;
Use of PD-1 or PD-L1 inhibitors in prior adjuvant or neoadjuvant phase;
patients with prior adjuvant or neoadjuvant phase use of apatinib mesylate and patients with prior treatment with vascular endothelial growth inhibitor-targeted agents such as sunitinib, sorafenib, bevacizumab, imatinib, famitinib, pazopanib, regorafenib, and erlotinib.
Trial design
Treatments tested in this trial
- Liposomal Doxorubicin (Doxil)
- Apatinib
- Camrelizumab
Treatment groups
49 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov